Viridian Therapeutics (VRDN) Earnings Date, Estimates & Call Transcripts → Urgent Nvidia Warning (From Altimetry) (Ad) Free VRDN Stock Alerts $13.90 -0.01 (-0.07%) (As of 05/10/2024 ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Earnings SummaryUpcoming Earnings DateAug. 13EstimatedActual EPS (May. 8) -$0.79 Beat By $0.28 Consensus EPS (May. 8) -$1.07 Read Call TranscriptListen to CallLatest SEC 10-Q Filing Get Viridian Therapeutics Earnings AlertsEnter your email address below to receive the latest news and earnings results for VRDN and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueVRDN Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.VRDN Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Weiss RatingsThe ONE AI Stock to own now. (It’s not Nvidia.)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages of this boom were big … But I believe the real wealth in AI has yet to be made …Click here to see the presentation now. Viridian Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20244($0.99)($0.89)($0.93)Q2 20245($0.90)($0.80)($0.83)Q3 20245($1.10)($0.80)($0.94)Q4 20245($1.17)($0.81)($0.92)FY 202419($4.16)($3.30)($3.63)Q1 20251($0.93)($0.93)($0.93)Q2 20251($0.97)($0.97)($0.97)Q3 20251($0.92)($0.92)($0.92)Q4 20251($0.95)($0.95)($0.95)FY 20254($3.77)($3.77)($3.77)VRDN Earnings Date and InformationViridian Therapeutics last announced its quarterly earnings data on May 8th, 2024. The reported ($0.79) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.07) by $0.28. The business had revenue of $0.07 million for the quarter, compared to the consensus estimate of $0.09 million. Its quarterly revenue was down 26.5% compared to the same quarter last year. Viridian Therapeutics has generated ($4.50) earnings per share over the last year (($4.50) diluted earnings per share). Earnings for Viridian Therapeutics are expected to remain at ($4.20) per share in the coming year. Viridian Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 13th, 2024 based off prior year's report dates.Read More Viridian Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 8/13/2024Estimated)------- 5/8/2024Q1 2024($1.07)($0.79)+$0.28($0.79)$0.09 million$0.07 million 2/27/2024Q4 2023($0.98)($1.35)($0.37)($1.35)$0.15 million$0.07 million11/13/2023Q3 2023($1.22)($1.09)+$0.13($1.09)$0.28 million$0.07 million8/8/2023Q2 2023($1.26)($1.27)($0.01)($1.27)$0.25 million$0.07 million5/9/2023Q1 2023($1.00)($1.61)($0.61)($1.61)$0.10 million$0.10 million 3/8/2023Q4 2022($0.72)($1.13)($0.41)($1.13)$0.46 million$0.11 million Get the Latest News and Ratings for VRDN and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Viridian Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 11/14/2022Q3 2022($0.87)($0.86)+$0.01($0.86)$0.52 million$1.20 million8/15/2022Q2 2022($0.86)($1.06)($0.20)($1.06)$0.70 million$0.26 million 5/12/2022Q1 2022($0.92)($0.98)($0.06)($0.98)$0.65 million$0.22 million 3/10/2022Q4 2021($0.85)($1.32)($0.47)($1.32)$0.75 million$0.21 million 11/4/2021Q3 2021($1.25)($1.25)-($1.25)$1.00 million$0.21 million8/11/2021Q2 2021($1.36)($2.21)($0.85)($2.21)-$1.09 million Viridian Therapeutics Earnings - Frequently Asked Questions When is Viridian Therapeutics's earnings date? Viridian Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 13th, 2024 based off last year's report dates. Learn more on VRDN's earnings history. Did Viridian Therapeutics beat their earnings estimates last quarter? In the previous quarter, Viridian Therapeutics (NASDAQ:VRDN) reported ($0.79) earnings per share (EPS) to beat the analysts' consensus estimate of ($1.07) by $0.28. Learn more on analysts' earnings estimate vs. VRDN's actual earnings. How can I listen to Viridian Therapeutics's earnings conference call? The conference call for Viridian Therapeutics's latest earnings report can be listened to online. Listen to Conference Call How can I read Viridian Therapeutics's conference call transcript? The conference call transcript for Viridian Therapeutics's latest earnings report can be read online. Read Transcript How can I view Viridian Therapeutics's earnings report? Viridian Therapeutics's earnings report can be found in their filing with the SEC. View SEC filing How much revenue does Viridian Therapeutics generate each year? Viridian Therapeutics (NASDAQ:VRDN) has a recorded annual revenue of $314,000.00. How much profit does Viridian Therapeutics generate each year? Viridian Therapeutics (NASDAQ:VRDN) has a recorded net income of -$237.73 million. VRDN has generated -$4.50 earnings per share over the last four quarters. What is Viridian Therapeutics's EPS forecast for next year? Viridian Therapeutics's earnings are expected to stay at ($4.20) per share in the next year. More Earnings Resources from MarketBeat Related Companies: Fulgent Genetics Earnings Castle Biosciences Earnings Celcuity Earnings CareDx Earnings Sera Prognostics Earnings Veracyte Earnings Psychemedics Earnings Guardant Health Earnings Arrowhead Pharmaceuticals Earnings Fortrea Earnings Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: Traders Sell but Investors Still Win After Palantir's EarningsTech Earnings Insights: Where Opportunity Meets UncertaintyApple’s Earnings Show Investors Its Strength and Its WeaknessCarvana’s Q1 Earnings: A Profitability U-TurnPayPal’s Strong Earnings Growth and Strategic Evolution GE Aerospace is Ready for Liftoff After Strong EarningsTaiwan Semiconductor Earnings: AI Dominance and Future Outlook This page (NASDAQ:VRDN) was last updated on 5/11/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe Crypto 9-5 Escape PlanCrypto 101 MediaUrgent Nvidia WarningAltimetryForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsObama’s Forever Term [exposed]Porter & CompanyBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viridian Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
